• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

2009 DF/HCC Biostatistics Program Dinner Workshop

<p>2009 DF/HCC Biostatistics Program Dinner Workshop<br /><br />The Biostatistics Program hosts an annual dinner to discuss topics related to biostatistics and computational biology as well as topics from related departments, such as population science and cancer biology. The purpose of the workshop is to bring program members together to learn about emerging areas in cancer research with substantial statistical content and encourage new collaborations. Speakers come from both inside and outside the DF/HCC community.<br /><br />2009 Workshop March 2, 2009<br />6:00-8:30 p.m.<br />CLSB Building, 3 Blackfan Circle, 11th Floor, room 11081<br /><br />Dinner is provided; RSVP required.<br />Email <a href="mailto:efeick@jimmy.harvard.edu">efeick@jimmy.harvard.edu</a> or go to <br /><a href="http://bcb.dfci.harvard.edu/dinnerworkshop">http://bcb.dfci.harvard.edu/dinnerworkshop</a> for more information.<br /><br />Image Analysis and Imaging Biomarkers in Oncology<br /><br />A. Gregory Sorensen, MD<br />Co-Director, MGH-HST A.A. Martinos Center, Associate Professor of <br />Radiology, HMS<br /><br />Title TBA<br /><br />Jeffrey Yap, PhD<br />Assistant Professor, Department of Radiology, DFCI and HMS<br /><br />&quot;Evaluating response to novel cancer therapy with PET/CT imaging:<br />Early development to global multi-center trials&quot;<br /><br />Abstract: Medical imaging plays a vital role in the development of novel <br />cancer therapies. Conventional anatomical imaging using CT or MRI is <br />most commonly used to evaluate therapeutic response based on changes in tumor morphology. However, there is often a delay in time before such <br />changes are detectable. Furthermore, molecular-targeted therapies may <br />result in effective treatment without reducing tumor size. Positron <br />Emission Tomography (PET) is a functional and molecular imaging modality that can be used to evaluate biochemical and physiological properties in tumors and normal tissues. Changes in such properties can be measured to evaluate the early effects of treatment before anatomical changes occur. More recently, widespread clinical use of combined PET/CT imaging has enabled these approaches to be implemented in large-scale clinical oncology trials. However, this requires simplification and standardization of the imaging methodology in order to achieve consistent and comparable results across the range of instrumentation and technical capabilities at different centers. This presentation will review the methods and applications of PET/CT imaging from early development of cancer therapies at single institutions to large scale multi-center trials.<br /><br />Armin Schwartzman<br />Assistant Professor, Department of Biostatistics and Computational <br />Biology, DFCI and HSPH<br /><br />&quot;Statistical Parametric Imaging for Response Assessment of Novel Therapy in Neuro-Oncology&quot;<br /><br />Abstract: Molecular-targeted therapy in cancer has been shown to <br />demonstrate early changes in glucose metabolic activity within one week <br />of treatment, as measured with FDG-PET using manual methods to identify and define tumor volumes. For longitudinal studies in neuro-oncology, a statistical analysis methodology is proposed to automate the detection and characterization of the changes at the voxel level to generate parametric images of response. The proposed methodology involves image-registration, statistical comparison at each voxel, and statistical thresholding of the generated parametric images.</p>

<p>Deadline to rsvp is Monday, February 23, 2009</p>